AURA: Volume dana dhuwit perusahaan Aura Biosciences

AURA (Aura Biosciences) - tandha merek perusahaan

Cash reserve dynamics demonstrate that the metric level stands at 0.30. Aura Biosciences, Inc. (AURA) relies on strict temperature control during the delivery of drugs to clinics to maintain business efficiency. Unique laser particles that preserve patient vision drive high demand. Meanwhile, the company's environmental policy is limited to the safe disposal of chemical waste in research laboratories.

Cadangan dhuwit perusahaan: Aura Bio (AURA) kanggo 04.07.2022 - 22.11.2026

Rincian metrik lan analitis perusahaan Aura Biosciences (AURA)

Analisis dhasar perusahaan:Aura Biosciences Inc
Produk merek aurabiosciences.com

For Aura Biosciences, Inc. (AURA), which develops targeted cancer therapies, liquidity levels dictate the pace of innovation commercialization. This metric measures available cash reserves, allowing for an assessment of financial stability and default risk while excluding illiquid assets. By analyzing current cash levels, an investor compares capital against industry benchmarks to identify resource surpluses or deficits. This is critical for expanding the patient base upon the approval of new products.

Pesaing Aura Biosciences, Inc. (AURA)

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|BCAX: Volume dana dhuwit perusahaan|PSNL - Aset likuid perusahaan|ERAS (Erasca Inc) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Delcath Systems Inc DCTH|Dana dhuwit perusahaan YmAbs (YMAB)|CADL (Candel Therapeutics, Inc.) - Sisa dhuwit perusahaan|Dana dhuwit perusahaan Accuray Inc ARAY|Aset likuid perusahaan SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Citius Oncology|HURA: Volume dana dhuwit perusahaan|Total volume dana dhuwit perusahaan TARA (Protara)|FATE (fatetherapeutics.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Aadi Bioscience WHWK|Volume dana dhuwit perusahaan TCRX|CSBR - Cadangan dhuwit perusahaan|XBiotech - Dhuwit awis perusahaan|CEL-SCI Corporation (CVM) - Cadangan dhuwit perusahaan|OSTX - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Dhuwit awis perusahaan|ANL (Adlai Nortye Ltd) - Dana dhuwit perusahaan|Dhuwit awis perusahaan VERU|Tempest Therapeutics (TPST) - Aset likuid perusahaan|Volume dana dhuwit perusahaan XLO|Dhuwit awis perusahaan Renovaro RENB|Volume dana dhuwit perusahaan MURA (Mural Oncology PLC)|KAPA - Dhuwit awis perusahaan|OnKure Therapeutics - Volume dana dhuwit perusahaan|w2.cytomed.sg - Gunggung dana dhuwit perusahaan|Curis Corp (CRIS) - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Apollomics Corp (APLM)|Dana dhuwit perusahaan Tharimmune|Volume dana dhuwit perusahaan advanbiomed.com|Dana dhuwit perusahaan Genprex, Inc (GNPX)|Aset likuid perusahaan Calidi Biotherapeutics, Inc.|Volume dana dhuwit perusahaan SBFM (Sunshine Biopharma Inc.)|XBIO - Dhuwit awis perusahaan|SLRX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PPBT (Purple Biotech Ltd.)|AONC: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan BeOne Medicines (BGNE)|Dana dhuwit perusahaan Checkpoint Therapeutics, Inc.|Dhuwit awis perusahaan Elevation Oncology (ELEV)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan